

Drug Policy

| | | |
|----------------|-------------------------------|---|
| Policy: | Pemazyre (pemigatinib) | Annual Review Date: 05/21/2020 Last Revised Date: 05/21/2020 |
|----------------|-------------------------------|---|

OVERVIEW

Pemazyre is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

POLICY STATEMENT

This policy involves the use of Pemazyre. Prior authorization is recommended for pharmacy benefit coverage of Pemazyre. Approval is recommended for those who meet the conditions of coverage in the **Criteria and Initial/Extended Approval** for the diagnosis provided. **Conditions Not Recommended for Approval** are listed following the recommended authorization criteria. Requests for uses not listed in this policy will be reviewed for evidence of efficacy and for medical necessity on a case-by-case basis.

Because of the specialized skills required for evaluation and diagnosis of patients treated with Pemazyre as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Pemazyre be prescribed by or in consultation with a physician who specializes in the condition being treated. In order to be considered for coverage, Pemazyre must be prescribed by or in consultation with a hematologist or oncologist. All approvals for initial therapy are provided for the initial approval duration noted below.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Pemazyre is recommended in those who meet the following criteria:

1. Cholangiocarcinoma

Criteria. *Patient must meet the following criteria*

- A. The patient is 18 years of age or older; AND
- B. The patient has previously been treated with at least one systemic therapy regimen; AND
- C. The patient has unresectable locally advanced, or metastatic disease; AND
- D. The patient has a fibroblast growth factor receptor-2 (FGFR2) fusion or rearrangement, as detected by an FDA-approved test.

Drug Policy

2. **Patients with another indication that is not listed but is cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation**

Criteria. *Prescriber will provide specific diagnosis for documentation. Approve.*

3. **Patient has been started on Pemazyre**

Criteria. *Approve for an indication or condition addressed as an approval in this document.*

Initial Approval/ Extended Approval.

A) *Initial Approval:* 1 year

B) *Extended Approval:* 1 year

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Pemazyre has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval).

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company.

Documentation requested may include patient records, test results and/or credentials of the provider ordering or performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

REFERENCES

1. Pemazyre [prescribing information]. Wilmington, DE: Incyte Corporation; April 2020.
2. The NCCN Hepatobiliary Cancers Clinical Practice Guidelines in Oncology (Version 1.2020 – March 23, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed on April 19, 2020.
3. The NCCN Drugs and Biologics Compendium. © 2020 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed 21 May 2020.
4. Pemigatinib. In: DRUGDEX [online database]. Truven Health Analytics; Greenwood Village, CO. Last updated 22 April 2020. Accessed 21 May 2020.